Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF in Ovaries With Low Follicular Reserve
NCT02992756Phase 3Terminated
- Sponsor
- International Vaccine Institute
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of PRGF-Endoret in Diminished Ovarian Reserve (DOR), sponsored by International Vaccine Institute. Started Jun 2021; status: terminated.
02
Drugs
PRGF-Endoret
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT02992756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992756.